Omeros prepares US launch of Omidria

Omeros said that it is lining up resources for the US launch in early 2015 of Omidria (phenylephrine and ketorolac injection) having been granted transitional pass-through reimbursement status for the drug by the Centers for Medicare & Medicaid Services. Preparations for the Omidria's commercial launch of Omidria— approved by FDA for use in cataract surgery and interocular lens replacement in June 2014--include securing an additional manufacturing source for the drug and contracting for 20 additional field sales reps. The Omidria sales force has already begun calling on surgeons, hospitals and ambulatory surgery centers, the company reports. The pass-through status allows for a separate payment for new drugs and medical technologies that meet specific clinical-value and cost requirements. Ambulatory surgery centers and other outpatient facilities are then permitted to bill Medicare and other insurance provides for Omidria. Omeros said it expects the status to remain in effect for two to three years, after which CMS will make a new reimbursement determination.


Next Article in Payers/Managed Markets